An observational study in Diabetes Mellitus, Type 2 and Cancer, sponsored by Azienda Ospedaliero Universitaria Maggiore della Carita. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Azienda Ospedaliero Universitaria Maggiore della Carita · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy — 45 open to participants now, 61 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Italy.
Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, this one is the 46th largest by planned enrollment of the 99 observational ones that give a count, is one of 22 that started in 2024, is one of 99 observational ones, reaches primary completion later than 6 of the 60 other live ones, and was the 368th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →45 of the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Italy, United States, Argentina and 13 more countries
Ages 45+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Italy, United States, Argentina and 12 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Brazil and 8 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
421 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 44 · Phase 3 157 · Phase 4 54
First in 1997; this study’s year is marked. 22 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 779 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 320 across the 321 interventional studies, 500 across the 99 observational. Of the 317 that completed or were terminated, 132 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
227 of 421 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero Universitaria Maggiore della Carita is the lead sponsor of 55 studies on the registry; 17 are open to participants now.
Azienda Ospedaliero Universitaria Maggiore della Carita has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetes Mellitus, Type 2 with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07149610Marche Region Regional Health AgencyConnected Care for Type 2 Diabetes Self-Management | 2026-11-30 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07783893Marche Region Regional Health AgencyE-Health Literacy Intervention for Bangladeshi Migrants With Type 2 Diabetes in Italy | 2026-12 |
| NCT05759637Istituto Auxologico ItalianoType 2 Diabetes, Obesity and Cortisol Excess | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recent research has highlighted the significant relationship between type 2 diabetes mellitus and cancer, both prevalent and impactful on global health. The intrinsic correlation arises from shared metabolic processes, particularly a systemic and chronic inflammatory state driven by factors like obesity, dyslipidemia, and hyperglycemia. This leads to the creation of a self-sustaining microenvironment known as meta-inflammation, promoting cancer development through DNA damage, oxidative stress, and the influence of hormones like leptin. The hyperglycemic environment in diabetes contributes to cancer development, supporting the Warburg effect and insulin-related mechanisms. This study aims to identify risk factors associated with diabetes that impact tumor development and progression, crucial for guiding effective preventive strategies in clinical practice.
Primary objective of the study:
- identify the risk factors affecting the occurrence of cancer in the population affected by type 2 diabetes mellitus;
Secondary objectives of the study:
Study design This study is a monocentric retrospective cohort study based on the data available in the Smart Digital Clinic (Meteda Srl) electronic medical record.
Participating centre Surgery of Endocrinology and Diabetology of the SCDU of Novara, University of Eastern Piedmont. Responsible: Prof.ssa Flavia Prodam
Subjects Will be included in the study all patients visited at the Endocrinology and Diabetology surgery of the AOU Major of the Charity of Novara for an initial diagnosis of diabetes mellitus type 2 between 1990 and 2010.
Inclusion criteria
Duration of study: 24 months
Follow-up and events of interest Patients included in the study will be followed from the date of diagnosis of type 2 diabetes mellitus until the date of the last available examination.
During the follow-up, for all patients included, the year of onset of the first cancer after the diagnosis of diabetes and the type of tumor will be detected. From this information it will be possible to calculate the time between the diagnosis of diabetes and the onset of cancer (measured in years).
For patients who have developed a first tumor will also be detected:
Data collection
For each patient, the following variables will be extracted from the Smart Digital Clinic electronic medical record for all visits available after diagnosis, where possible:
BMI categories will be divided into underweight (BMI \<18.5 Kg/m2), normal weight (BMI 18.5 - 25 Kg/m2), and overweight (BMI >25 Kg/m2).
With regard to the treatment of type 2 diabetes mellitus, participants will be categorised and grouped for statistical purposes in the following classes:
Finally, as regards cancer pathology, a categorization of treatment will be carried out in three classes: chemotherapy, surgery and radiation therapy.
In addition, the types of cancer will be divided in order to ensure greater homogeneity between groups, including the nervous system, head and neck, thorax, gastrointestinal, gynecological, urinary tract, male genital system, skin, blood, breast, soft tissues, endocrine glands and neuroendocrine tumors. This information will be collected at the diabetes diagnosis visit and at the last visit before the onset of cancer for the subjects experiencing the event and at the last available visit for the remaining subjects.
EXPECTED RESULTS Through this research, the investigators aim to obtain new information on the study population in order to better understand the possible correlation between the two pathologies. This will allow us to identify the risk factors associated with metabolic pathology that can affect the development time of cancer pathologies, as well as to identify those that could contribute to carcinogenesis itself.
This knowledge will allow us to define the role of hyperglycemia, obesity and other factors or behaviors at risk in the field of cancer in order to act with appropriate prevention strategies, thus considering the tumor pathology as one of the possible complications of type 2 diabetes mellitus.
779 patients with diabetes mellitus type 2 and with at least 18 years old.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
779 patients with cancer and diagnosis of type 2 diabetes mellitus diagnosed between 1990 and 2010
Other: phenotyping of patients followed at a third-level diabetes centre with cancer
Collection of the following data for each patient enrolled, where possible: * Gender and age; * Smoking habits and alcohol consumption (units per day); * Weight and body mass index (BMI) at first (T0) and last visit (T1); * Given by the diagnosis of type 2 diabetes mellitus; * Treatment of type 2 diabetes at T0 and T1; * Levels of glycated hemoglobin (hba1c) at T0 and T1, mean hba1c and mean fasting blood sugar; * Creatinine clearance at T0 and T1; * Liver enzymes at T0 and T1: alanine aminotransferase (ALT) and aspartate aminotransferase (AST); * T0 and T1 lipid profile: low density lipoproteins (LDL-c) and triglycerides (TG); * Complications of type 2 diabetes; * Treatment of cancer; * Family history of cancer.
Smoking assessment at first visit
identify the risk factors affecting the occurrence of cancer in the population affected by type 2 diabetes mellitus: During the first examination, the history of each patient was investigated, evaluating whether they were smokers, non-smokers or ex smokers
Time frame: Assessment of data at time 0 (first clinical visit)
Alcool consumption at first visit
identify the risk factors influencing the onset of cancer in the population affected by type 2 diabetes mellitus: During the first examination, the history of each patient was studied, assessing whether I consume alcohol and in what amount. \<1 alcohol unit or greater than 2 alcohol units were used as cutoffs to subdivide the patients considered.
Time frame: Assessment of data at time 0 (first clinical visit)
BMI assessment at first visit
identify the risk factors influencing the onset of cancer in the population affected by type 2 diabetes mellitus: During the first examination, the history of each patient was studied, measuring weight and height to calculate the BMI of each patient. The ranges considered are: underweight \<18.5, normal weight 18.5-25 and overweight \>25.
Time frame: Assessment of data at time 0 (first clinical visit)
Glycated assessment at first visit
identify the risk factors influencing the onset of cancer in the population affected by type 2 diabetes mellitus: During the first examination, the history of each patient was studied, measuring the glycate of each patient. The considered cutoff is \< or equal to 8%, where 8% is the limit for glycemic decompensation.
Time frame: Assessment of data at time 0 (first clinical visit)
First-line therapy characteristics assessment at first visit
Detection of drug therapy given at the first visit considering the medical record. The therapies considered were: Dietotherapy, Metformin/Acarbosio, Sulfanilurea, Metformin + GLP1/DDPIVi or GLP1 alone or DDDPIVi alone, Metformin + SGLT2i or SGLT2i alone, Basal insulin + GLP1/DPIVi +/- Metformin, Basal Insulin +/- Metformin + SGT2i, Insulin Basal Bolus, Insulin Basal Bolus +/- Metformin +/- SGLT2i
Time frame: Assessment of data at time 0 (first clinical visit)
Primary outcomes and recurrence or presence of a secondary tumor
Considering the risk factors measured as primary findings, it was intended to observe a possible association with those who had recurrence or with the development of a secondary tumour unrelated to the first, within 10 years of the diagnosis of diabetes. Detected during first clinical visit signed in the medical record
Time frame: Assessment of data at time 0 (first clinical visit)
Relationship between patients characteristics and the time onset of cancer considering anthropometric and biochemical data
Assess the relationship between the characteristics of patients and the time to the onset of cancer using medical record
Time frame: Assessment of data at time 0 (first clinical visit)
Tumour characterization in the considered population, detected at the first clinical visit
Characterization of tumors: tumors of the nervous system, head neck, thoracic, gastrointestinal, gynecological, urological, male genital, cutaneous, haematological, breast, soft tissue, endocrine glands, neuroendocrine and bone tumors. Detected during first clinical visit considering the medical record.
Time frame: Assessment of data at time 0 (first clinical visit)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2024 to primary completion in Feb 2025, 12 months.
Completion moved once since we started tracking on Sep 25, 2026: Feb 2025 → Feb 2027, on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero Universitaria Maggiore della Carita